116 related articles for article (PubMed ID: 36595540)
1. Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.
Mascarella MA; Olonisakin TF; Rumde P; Vendra V; Nance MA; Kim S; Kubik MW; Sridharan SS; Ferris RL; Fenton MJ; Clayburgh DR; Ohr JP; Joyce SC; Sen M; Herman JG; Grandis JR; Zandberg DP; Duvvuri U
Clin Cancer Res; 2023 Feb; 29(4):723-730. PubMed ID: 36595540
[TBL] [Abstract][Full Text] [Related]
2. Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Kiong KL; Bell D; Yao CM; Ferrarotto R; Lewis CM
Oral Oncol; 2021 Nov; 122():105520. PubMed ID: 34521029
[TBL] [Abstract][Full Text] [Related]
3. Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes.
Kiong KL; Yao CMKL; Lin FY; Bell D; Ferrarotto R; Weber RS; Lewis CM
Cancer; 2021 Jun; 127(12):1984-1992. PubMed ID: 33631040
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.
Duvvuri U; George J; Kim S; Alvarado D; Neumeister VM; Chenna A; Gedrich R; Hawthorne T; LaVallee T; Grandis JR; Bauman JE
Clin Cancer Res; 2019 Oct; 25(19):5752-5758. PubMed ID: 31308059
[TBL] [Abstract][Full Text] [Related]
6. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
Bauman JE; Duvvuri U; Gooding WE; Rath TJ; Gross ND; Song J; Jimeno A; Yarbrough WG; Johnson FM; Wang L; Chiosea S; Sen M; Kass J; Johnson JT; Ferris RL; Kim S; Hirsch FR; Ellison K; Flaherty JT; Mills GB; Grandis JR
JCI Insight; 2017 Mar; 2(6):e90449. PubMed ID: 28352657
[No Abstract] [Full Text] [Related]
7. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Feng Z; Guo W; Zhang C; Xu Q; Zhang P; Sun J; Zhu H; Wang Z; Li J; Wang L; Wang B; Ren G; Ji T; Tu W; Yang X; Qiu W; Mao L; Zhang Z; Chen W
PLoS One; 2011; 6(10):e26399. PubMed ID: 22065993
[TBL] [Abstract][Full Text] [Related]
8. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
10. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Yang L; Huang Y; Zhou L; Dai Y; Hu G
Head Neck; 2019 May; 41(5):1525-1535. PubMed ID: 30597654
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.
Pajares B; Perez-Villa L; Trigo JM; Toledo MD; Alvarez M; Jimenez B; Medina JA; de Luque V; Jerez JM; Alba E
Clin Transl Oncol; 2014 Apr; 16(4):418-24. PubMed ID: 24193865
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Konschak R; Stromberger C; Raguse JD; Dreyer JH; Jöhrens K; Keilholz U; Budach V
Ann Oncol; 2014 Oct; 25(10):2042-2047. PubMed ID: 25057171
[TBL] [Abstract][Full Text] [Related]
16. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer.
Zhao Y; Wucherpfennig KW
Curr Opin Oncol; 2024 May; 36(3):136-142. PubMed ID: 38573202
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
19. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
